Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06631157 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Essential Pro Study ( rEPIC04E-HK )

Study acronym: rEPIC04E-HK
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Nov 1, 2025 to Nov 1, 2026v3
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 1, 2024 to May 15, 2025 · Study sites: 0 to 1v2 Show 2 more changesShow less
    • Start date changed from estimate of Nov 1, 2024 to May 15, 2025
    • Study sites: 0 to 1
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Single center, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.
Trial Details
NCT Number NCT06631157
Lead Sponsor Fundación EPIC
Conditions Coronary Artery Disease, Ischemic Heart Disease
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov